Combination of Vandetanib, Radiotherapy, and Irinotecan in the LoVo Human Colorectal Cancer Xenograft Model

Journal Article · Sun Nov 01 00:00:00 EDT 2009 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2009.06.016· OSTI ID:21362225

Wachsberger, Phyllis ^[1]; Burd, Randy ^[2]; Ryan, Anderson ^[3]; Daskalakis, Constantine ^[4]; Dicker, Adam P ^[1]

---

1. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA (United States)
2. Department of Nutritional Sciences, University of Arizona, Tucson, AZ (United States)
3. AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield (United Kingdom)
4. Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA (United States)

Purpose: The tumor growth kinetics of the human LoVo colorectal xenograft model was assessed in response to vandetanib, an orally available receptor tyrosine kinase inhibitor, radiotherapy (RT), or irinotecan (CPT-11), as single therapies and in combination. Methods and Materials: LoVo cells were injected subcutaneously into the right hind limb (5x10{sup 6} cells in 100muL phosphate-buffered saline) of athymic NCR NUM mice and tumors were grown to a volume of 200-300 mm{sup 3} before treatment. Vandetanib was administered at 50 mg/kg daily orally for 14 days starting on Day 1. RT was given as three fractions (3x3 Gy) on Days 1, 2, and 3. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Tumor volumes were measured on a daily basis and calculated by measuring tumor diameters with digital calipers in two orthogonal dimensions. Results: All three single treatments (vandetanib, CPT-11, and radiation) significantly slowed LoVo colorectal tumor growth. Vandetanib significantly increased the antitumor effects of CPT-11 and radiation when given in combination with either of these treatments. These treatment combinations resulted in a slow tumor growth rate during the 2 weeks of vandetanib administration. The triple combination of vandetanib, CPT-11, and radiation produced the most marked improvement in response as observed by measurable shrinkage of tumors during the first week of treatment. Conclusions: The tumor growth delay kinetics observed in this study of the LoVo colorectal model suggest concurrent and sustained post-sequencing of vandetanib with cytotoxic therapy may be beneficial in tumors of this type.

• OSTI ID: 21362225
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 75, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2009.06.016; PII: S0360-3016(09)00917-1; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
GROWTH
KINETICS
LARGE INTESTINE
NEOPLASMS
RADIOTHERAPY
RECEPTORS
TYROSINE
AMINO ACIDS
BODY
CARBOXYLIC ACIDS
DIGESTIVE SYSTEM
DISEASES
GASTROINTESTINAL TRACT
HYDROXY ACIDS
INTESTINES
MEDICINE
MEMBRANE PROTEINS
NUCLEAR MEDICINE
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANS
PROTEINS
RADIOLOGY
THERAPY